4 results
To investigate the potential influence of time of dosing (morning or evening)on the bronchodilator effect of once daily orally inhaled QVM149 compared toplacebo.
To determine the effect size of PRM-151 relative to placebo in change from Baseline to Week 28 in mean FVC% predicted, pooling subjects on a stable dose of pirfenidone or nintedanib and subjects not on other treatment for IPF.
To determine the effect size of three different doses of PRM-151 on reduction in bone marrow fibrosis by * 1 grade in intermediate-1, intermediate-2, and high risk subjects with PMF, post-PV MF, or post ET-MF who are anemic or thrombocytopenic and…
Demonstrate an increase of 2-year overall survival (OS) of 15 % (from 50% to 65 %) vs historical controls of the addition of nitroglycerin to radiotherapy (±chemotherapy) of stage I-IV NSCLC.